Inovio Pharmaceuticals (NASDAQ:INO) Rating Lowered to Sell at StockNews.com

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) was downgraded by stock analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Friday.

A number of other brokerages have also recently issued reports on INO. Oppenheimer upgraded Inovio Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $48.00 price objective on the stock in a research note on Thursday, January 25th. JMP Securities started coverage on Inovio Pharmaceuticals in a research note on Thursday, January 4th. They set a "market outperform" rating and a $144.00 price objective on the stock. Finally, Royal Bank of Canada reiterated a "sector perform" rating on shares of Inovio Pharmaceuticals in a research note on Thursday, March 7th.

Inovio Pharmaceuticals Stock Performance

NASDAQ INO traded down $0.15 during trading on Friday, hitting $11.80. The stock had a trading volume of 233,855 shares, compared to its average volume of 550,638. The company has a market capitalization of $275.65 million, a PE ratio of -1.56 and a beta of 1.11. The company's 50-day moving average price is $9.25 and its two-hundred day moving average price is $46.54. Inovio Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $14.75.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Legal & General Group Plc lifted its holdings in Inovio Pharmaceuticals by 2.7% during the second quarter. Legal & General Group Plc now owns 165,053 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 4,314 shares during the period. Nuveen Asset Management LLC raised its stake in shares of Inovio Pharmaceuticals by 0.4% in the third quarter. Nuveen Asset Management LLC now owns 1,160,135 shares of the biopharmaceutical company's stock valued at $2,001,000 after buying an additional 4,553 shares during the period. Quantbot Technologies LP raised its stake in shares of Inovio Pharmaceuticals by 10.0% in the first quarter. Quantbot Technologies LP now owns 57,000 shares of the biopharmaceutical company's stock valued at $204,000 after buying an additional 5,200 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in shares of Inovio Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 115,361 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 6,148 shares during the period. Finally, Hsbc Holdings PLC grew its position in shares of Inovio Pharmaceuticals by 15.7% in the first quarter. Hsbc Holdings PLC now owns 47,672 shares of the biopharmaceutical company's stock valued at $171,000 after purchasing an additional 6,475 shares in the last quarter. Institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.